InnoCare Pharma Limited
InnoCare Pharma Limited Fundamental Analysis
InnoCare Pharma Limited (9969.HK) shows moderate financial fundamentals with a PE ratio of 24.38, profit margin of 28.78%, and ROE of 10.12%. The company generates $2.1B in annual revenue with weak year-over-year growth of 1.28%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 9969.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak9969.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent9969.HK trades at attractive valuation levels.
Growth Score
Weak9969.HK faces weak or negative growth trends.
Financial Health Score
Excellent9969.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate9969.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 9969.HK Expensive or Cheap?
P/E Ratio
9969.HK trades at 24.38 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 9969.HK's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values InnoCare Pharma Limited at 2.40 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 29.81 times EBITDA. This signals the market has high growth expectations.
How Well Does 9969.HK Make Money?
Net Profit Margin
For every $100 in sales, InnoCare Pharma Limited keeps $28.78 as profit after all expenses.
Operating Margin
Core operations generate 23.70 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.12 in profit for every $100 of shareholder equity.
ROA
InnoCare Pharma Limited generates $6.95 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
InnoCare Pharma Limited generates limited operating cash flow of $89.05M, signaling weaker underlying cash strength.
Free Cash Flow
InnoCare Pharma Limited generates weak or negative free cash flow of $25.40M, restricting financial flexibility.
FCF Per Share
Each share generates $0.02 in free cash annually.
FCF Yield
9969.HK converts 0.20% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
24.38
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.40
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.95
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.65
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How 9969.HK Stacks Against Its Sector Peers
| Metric | 9969.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 24.38 | 28.32 | Better (Cheaper) |
| ROE | 10.12% | 733.00% | Weak |
| Net Margin | 28.78% | -53055.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 5.65 | 4.03 | Strong Liquidity |
| ROA | 6.95% | -19488.00% (disorted) | Weak |
9969.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews InnoCare Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
92387.21%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
187.80%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
163.38%
Industry Style: Defensive, Growth, Innovation
High Growth